OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)

NCT02097121 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
56
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Allergan